Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,879 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Expectant Management Clear all
Completed Not applicable Interventional Results available

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

NCT02135484
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alpharadin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 21, 2026, 3:41 AM EDT
Recruiting Phase 2 Interventional

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614
View directory record Official record
Conditions
Nonmuscle-invasive Bladder Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

NCT01205035
View directory record Official record
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional

Severe Intrauterine Growth Retardation: Developmental Newborn Intensive Care Unit (NICU) Care

NCT00914108
View directory record Official record
Conditions
Intrauterine Growth Retardation, Prematurity
Interventions
Newborn Individualized Developmental Care
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 36 Weeks
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Terminated No phase listed Observational Results available

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

NCT00151476
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
Celecoxib, Routine Medical Care
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

Scoliosis-Specific Exercises for At-Risk AIS Curves

NCT02807545
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Scoliosis Specific Exercises
Behavioral
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
10 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 3 Interventional

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

NCT00095719
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
14
States / cities
Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 21, 2026, 3:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Emotion Regulation Strategies in Toddlerhood and Middle Childhood

NCT05415319
View directory record Official record
Conditions
Emotion Regulation
Interventions
Laboratory tasks in middle childhood/pre-adolescence
Behavioral
Lead sponsor
Miami University
Other
Eligibility
8 Years to 14 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 21, 2026, 3:41 AM EDT
Not listed No phase listed Observational

Assessing the Predictive Value of High Frequency Algorithm of PURE EP for Low Amplitude Signal Detection

NCT05450302
View directory record Official record
Conditions
Cardiac Arrhythmias
Interventions
PURE EP (Observational Study)
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 21, 2026, 3:41 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

NCT03038477
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Durvalumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 21, 2026, 3:41 AM EDT
Recruiting No phase listed Observational

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

NCT06887348
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
Observational study with no interventions
Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Not listed Phase 2 Interventional

Secretin for Acute Pancreatitis

NCT03686618
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Genetic Modifiers for 22q11.2 Syndrome

NCT00916955
View directory record Official record
Conditions
22q11.2 Deletion Syndrome
Interventions
Observation
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

Genomics in Michigan Impacting Observation or Radiation

NCT02783950
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Prostate Cancer Classifier
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
13
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease

NCT00790543
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
5 Days to 16 Years
Enrollment
1,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
25
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 3:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SGN1 in Patients With Advanced Solid Tumor

NCT05038150
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SGN1
Drug
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Not listed Not applicable Interventional

Monitored Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia

NCT02902887
View directory record Official record
Conditions
Intermittent Exotropia
Interventions
Controlled Intermittent Alternate Occlusion (CIAO ) glasses
Device
Lead sponsor
Salus University
Other
Eligibility
3 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Identification of Tongue Involvement in Late-Onset Pompe Disease

NCT02765828
View directory record Official record
Conditions
Myopathy, Neuropathy, Glycogen Storage Disease Type II (Late-onset Pompe Disease)
Interventions
Observational study
Other
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

NCT00454571
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
pazopanib hydrochloride, leuprolide acetate, goserelin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

StandUPTV: Reducing Sedentary Screen Time in Adults

NCT04464993
View directory record Official record
Conditions
Sedentary Behavior, Screen Time, Physical Activity, Sleep
Interventions
Device-based feedback, self-monitoring, and education: CORE, Sedentary Screen Time lockout: LOCKOUT, Context-based prompts: TEXT, Earn sedentary screen time through moderate-vigorous physical activity: EARN
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
23 Years to 64 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Tempe, Arizona • San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Circulating Tumor Cells in Solid Tumors

NCT03161821
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Observational
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 3:41 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cleidocranial Dysplasia (CCD): From Genotype to Phenotype and Considerations for Care

NCT05368064
View directory record Official record
Conditions
Cleidocranial Dysostosis
Interventions
observational
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Changes in Adolescents While Imagining and Observing Aggressive Behavior

NCT00267891
View directory record Official record
Conditions
Aggressive Behavior
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
14 Years to 17 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00669318
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
alemtuzumab, rituximab, pentostatin, sargramostim
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Iowa City, Iowa • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 21, 2026, 3:41 AM EDT